Matrix metalloproteinases as mediators of tissue injury in different forms of cutaneous lupus erythematosus

British Journal of Dermatology

Volumn 157, Issue 5, 2007, Pages 970-980

  Jarvinen T M ^a   Kanninen, P ^a   Jeskanen, L ^a   Koskenmies, S ^a,b   Panelius, J ^a   Hasan, T ^c   Ranki, A ^a   Saarialho Kere, U ^a,d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Apoptosis; Immunohistochemistry; MMP 10; MMP 14; MMP 26; TIMP

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 26; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL VACUOLE; ENDOTHELIUM CELL; EPIDERMIS CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; TISSUE INJURY; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CASE-CONTROL STUDIES; EPIDERMIS; FEMALE; HUMANS; IN SITU NICK-END LABELING; KERATINOCYTES; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, DISCOID; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 35348844214     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08166.x     Document Type: Article

References (38)

1. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006 24:348 62.
2. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for cutaneous lupus erythematosus. J Am Acad Dermatol 1996 34:830 6.
3. Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 2001 28:1 23.
4. Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post trial era. Nat Rev Cancer 2002 2:657 72.
5. Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004 4:617 29.
6. Ainiala H, Hietaharju A, Dastidar P et al. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum 2004 50:858 65.
7. Trysberg E, Blennow K, Zachrisson O et al. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther 2004 6:R551 6.
8. Mawrin C, Brunn A, Rocken C et al. Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathol 2003 105:365 72.
9. Faber-Elmann A, Sthoeger Z, Tcherniack A et al. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 2002 127:393 8.
10. Zucker S, Mian N, Drews M et al. Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. J Rheumatol 1999 26:78 80.
11. Kotajima L, Aotsuka S, Fujimani M et al. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin Exp Rheumatol 1998 16:409 15.
12. Sedlacek R, Mauch S, Kolb B et al. Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. Immunobiology 1998 198:408 23.
13. Robak E, Wierzbowska A, Chmiela M et al. Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with systemic lupus erythematosus. Mediators Inflamm 2006 1:17898.
14. Mandel M, Gurevich M, Pauzner R et al. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol 2004 138:164 70.
15. Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 2001 144:958 66.
16. Tsukinoki T, Sugiyama H, Sunami R et al. Mesangial cell Fas ligand: upregulation in human lupus nephritis and NF-kappaB-mediated expression in cultured human mesangial cells. Clin Exp Nephrol 2004 8:196 205.
17. Langlois S, Di Tomasso G, Boivin D et al. Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by caspase-dependent mechanism. Exp Cell Res 2005 307:452 64.
18. Nagavarapu U, Relloma K, Herron GS. Membrane type 1 matrix metalloproteinase regulates cellular invasiveness and survival in cutaneous epidermal cells. J Invest Dermatol 2002 118:537 81.
19. Salmela MT, Karjalainen-Lindsberg ML, Jeskanen L, Saarialho-Kere U. Overexpression of tissue inhibitor of metalloproteinases-3 in intestinal cutaneous lesions of graft-versus-host disease. Mod Pathol 2003 16:108 14.
20. Saarialho-Kere U, Kerkelä E, Jeskanen L et al. Accumulation of matrilysin (MMP-7) and macrophage metalloelastase (MMP-12) in actinic damage. J Invest Dermatol 1999 113:664 72.
21. Jerdan MS, Hood AF, Moore GW et al. Histopathologic comparison of the subsets of lupus erythematosus. Arch Dermatol 1990 126:52 5.
22. Kuivanen TT, Jeskanen L, Kyllönen L et al. Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas. Mod Pathol 2006 19:1203 12.
23. Impola U, Toriseva M, Suomela S et al. Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int J Cancer 2003 103:709 16.
24. Ahokas K, Skoog T, Suomela S et al. Matrilysin-2 (matrix metalloproteinase-26) is upregulated in keratinocytes during wound repair and early skin carcinogenesis. J Invest Dermatol 2005 124:849 56.
25. Airola K, Johansson N, Kariniemi L et al. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 1997 109:225 31.
26. Dazard JE, Gal H, Amariglio N et al. Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer. Oncogene 2003 22:2993 3006.
27. Kerkelä E, Ala-aho R, Lohi J et al. Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer 2001 84:659 69.
28. Krampert M, Bloch W, Sasaki T et al. Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell 2004 15:5242 54.
29. Madlener M, Mauch C, Conca W et al. Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. Biochem J 1996 320:659 64.
30. Vaalamo M, Weckroth M, Puolakkainen P et al. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol 1996 135:52 9.
31. Karelina TV, Goldberg GI, Eisen AZ. Matrilysin (PUMP) correlates with dermal invasion during appendageal development and cutaneous neoplasia. J Invest Dermatol 1994 103:482 7.
32. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001 13:534 40.
33. Ohnishi Y, Tajima S, Akiyama M et al. Expression of elastin-related proteins and matrix metalloproteinases in actinic elastosis of sun-damaged skin. Arch Dermatol Res 2000 292:27 31.
34. Mooney E, Gammon WR, Jeanette JC. Characterization of the changes in matrix molecules at the dermoepidermal junction in lupus erythematosus. J Cutan Pathol 1991 18:417 22.
35. Gunduz K, Demireli P, Inanir I et al. Expression of matrix metalloproteinases (MMP-2, MMP-3, and MMP-9) and fibronectin in lichen planus. J Cutan Pathol 2006 33:545 50.
36. Rus V, Chen H, Zernetkina V et al. Gene expression profiling in peripheral blood mononuclear cells from lupus patients with active and inactive disease. Clin Immunol 2004 112:231 4.
37. De Jong EMGJ, van Erp PEJ, Ruiter DJ et al. Immunohistochemical detection of proliferation and differentiation in discoid lupus erythematosus. J Am Acad Dermatol 1991 25:1032 8.
38. Kuhn A, Herrman M, Kleber S et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 2006 54:939 50.